According to the tribunal a 'minimal figure' of 250 haemophiliacs were infected with HIV or Hepatitis C while receiving treatment from the BTSB before 1985.
Haemophilia is a genetic condition where the blood does not clot as quickly as normal due to a deficiency in certain proteins.
Since 1992 recombinant proteins are generally used, which contain little, if any, human blood products - and thus have a negligible risk of contamination.
However, some of it came from American suppliers which included blood from prisoners and drug addicts, who had a high risk of infection.
The Tribunal criticised the National Haemophilia Centre for its slow response to the risk of HIV infection.